Teza Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Teza Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,681	Closed	-$477K	–	754
2024 Q1	$477K	Buy	+3,681	New	+$451K	0.06%	346
2023 Q4	–	Sell	-4,668	Closed	-$566K	–	742
2023 Q3	$566K	Buy	+4,668	New	+$528K	0.09%	294
2023 Q1	–	Sell	-3,587	Closed	-$465K	–	697
2022 Q4	$465K	Sell	3,587 -1,526	-30%	-$177K	0.09%	343
2022 Q3	$565K	Buy	5,113 +1,585	+45%	+$160K	0.12%	253
2022 Q2	$264K	Buy	+3,528	New	+$260K	0.1%	335
2021 Q3	–	Sell	-11,104	Closed	-$863K	–	572
2021 Q2	$863K	Buy	+11,104	New	+$842K	0.14%	196
2020 Q3	–	Sell	-10,049	Closed	-$1.61M	–	593
2020 Q2	$1.61M	Buy	+10,049	New	+$1.37M	0.36%	66

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Teza Capital Management's SRPT Position: Q2 2024 in Review

Teza Capital Management sold out of Sarepta Therapeutics (SRPT) in Q2 2024, closing a stake of 3,681 shares — an estimated $477K sold.

Teza Capital Management first reported a position in SRPT in Q2 2020 and held it in 7 quarters. The position peaked at $1.61M in Q2 2020. 483 funds tracked by Wall St. Rank hold SRPT as of Q2 2024.

Teza Capital Management reported no remaining Sarepta Therapeutics position as of Q2 2024 after selling out during the quarter.
Teza Capital Management sold 3,681 Sarepta Therapeutics shares in Q2 2024, an estimated $477K.
Teza Capital Management first reported a position in Sarepta Therapeutics in Q2 2020 and held it in 7 quarters.
Teza Capital Management's Sarepta Therapeutics position peaked at $1.61M in Q2 2020.
483 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2024.

Based on Teza Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.